Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer

Tumor Biology

Volumn 37, Issue 1, 2016, Pages 1299-1308

  Haghpanah, Vahid ^a   Fallah, Parviz ^b   Tavakoli, Rezvan ^c   Naderi, Mahmood ^c,d   Samimi, Hilda ^a   Soleimani, Masoud ^e   Larijani, Bagher ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ALBORZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c STEM CELL TECHNOLOGY RESEARCH CENTER   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Anaplastic thyroid cancer; Antisense miR 21; Apoptosis; Cancer stem cell; Differentiation

Indexed keywords

ANTAGOMIR; BREAST CANCER RESISTANCE PROTEIN; MICRORNA 21; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SODIUM IODIDE SYMPORTER; THYROGLOBULIN; TUMOR MARKER; ANTISENSE OLIGONUCLEOTIDE; APOPTOSIS REGULATORY PROTEIN; MCL1 PROTEIN, HUMAN; MICRORNA; MIRN21 MICRORNA, HUMAN; PDCD4 PROTEIN, HUMAN; PROTEIN MCL 1; RNA BINDING PROTEIN;

ANAPLASTIC THYROID CANCER; APOPTOSIS; ARTICLE; C643 CELL LINE; CANCER STEM CELL; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNORADIOMETRIC ASSAY; MALE; MCL 1 GENE; ONCOGENE; P21 GENE; PDCD4 GENE; PRIORITY JOURNAL; PTEN GENE; SW1736 CELL LINE; THYROID CANCER CELL LINE; UPREGULATION; CELL CYCLE; CELL PROLIFERATION; CYTOLOGY; GENETICS; METABOLISM; THYROID CARCINOMA; THYROID TUMOR; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MALE; MICRORNAS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDES, ANTISENSE; RNA-BINDING PROTEINS; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS;

EID: 84939605985     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3923-z     Document Type: Article

References (40)

1. Sipos J, Mazzaferri E. Thyroid cancer epidemiology and prognostic variables. Clin Oncol. 2010;22:395–404.
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7.
3. Pierie J-PE, Muzikansky A, Gaz RD, Faquin WC, Ott MJ. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol. 2002;9:57–64.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.
5. Guo Z, Hardin H, Lloyd RV. Cancer stem-like cells and thyroid cancer. Endocr Relat Cancer. 2014;21:T285–300.
6. Ma R, Minsky N, Morshed SA, Davies TF. Stemness in human thyroid cancers and derived cell lines: the role of asymmetrically dividing cancer stem cells resistant to chemotherapy. J Clin Endocrinol Metab. 2014;99:E400–E9.
7. Lin RY. Thyroid cancer stem cells. Nat Rev Endocrinol. 2011;7:609–16.
8. Gao Y-J, Li B, Wu X-Y, Cui J, Han J-K. Thyroid tumor-initiating cells: increasing evidence and opportunities for anticancer therapy (review). Oncol Rep. 2014;31:1035–42.
9. Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid. 2010;20:697–706.
10. Hill R, Wu H. PTEN, stem cells, and cancer stem cells. J Biol Chem. 2009;284:11755–9.
11. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol. 2006;155:495–512.
12. Paes JE, Ringel MD. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am. 2008;37:375–87.
13. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13:283–96.
14. Samimi H, Zaki dizaji M, Ghadami M, Shahzadeh fazeli A, Khashayar P, Soleimani M, et al. MicroRNAs networks in thyroid cancers: focus on miRNAs related to the fascin. J Diabetes MetabDisord. 2013;12:31.
15. Selcuklu SD, Donoghue MA. Spillane C: miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans. 2009;37:918–25.
16. Galderisi U, Cascino A, Giordano A. Antisense oligonucleotides as therapeutic agents. J Cell Physiol. 1999;181:251–7.
17. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263–7.
18. Naderi M, Abdul TH, Soleimani M, Shabani I, Hashemi SM: A home-brew real-time PCR assay for reliable detection and quantification of mature miR-122. Appl Immunohistochem Mol Morphol 2014.
19. Samimi H, Zaki dizaji M, Ghadami M, Shahzadeh fazeli A, Khashayar P, Soleimani M, et al. Essential genes in thyroid cancers: focus on fascin. J Diabetes MetabDisord. 2013;12:32.
20. Kang HY. MicroRNA-21 regulates stemness in cancer cells. Stem Cell Res Ther. 2013;4:110–3.
21. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008;93:4331–41.
22. Meireles AM, Preto A, Rocha AS, Rebocho AP, Máximo V, Pereira-Castro I, et al. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid. 2007;17:707–15.
23. Pilli T, Prasad KV, Jayarama S, Pacini F, Prabhakar BS. Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid. 2009;19:1333–42.
24. Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, et al. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma. J Nucl Med. 2012;53:1764–71.
25. Thomas T, Nowka K, Lan L, Derwahl M. Expression of endoderm stem cell markers: evidence for the presence of adult stem cells in human thyroid glands. Thyroid. 2006;16:537–44.
26. Niwa H, Miyazaki J-I, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 2000;24:372–6.
27. Zheng X, Cui D, Xu S, Brabant G, Derwahl M. Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells. Int J Oncol. 2010;37:307–15.
28. Fierabracci A. Identifying thyroid stem/progenitor cells: advances and limitations. J Endocrinol. 2012;213:1–13.
29. Kogai T, Taki K, Brent G. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer. 2006;13:797–826.
30. Lan L, Cui D, Nowka K, Derwahl M. Stem cells derived from goiters in adults form spheres in response to intense growth stimulation and require thyrotropin for differentiation into thyrocytes. J Clin Endocrinol Metab. 2007;92:3681–8.
31. Lankat-Buttgereit B, Göke R. Programmed cell death protein 4 (pdcd4): a novel target for antineoplastic therapy? Biol Cell. 2003;95:515–9.
32. Asangani I, Rasheed S, Nikolova D, Leupold J, Colburn N, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27:2128–36.
33. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 2003;17:1475–86.
34. Fernald K, Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol. 2013;23:620–33.
35. Stiles B, Groszer M, Wang S, Jiao J, Wu H. PTENless means more. Dev Biol. 2004;273:175–84.
36. Fata JE, Debnath S, Jenkins EC, Fournier MV. Nongenomic mechanisms of PTEN regulation. Int J Cell Biol. 2012;2012:379685.
37. Buscaglia L, Li Y. Apoptosis and the target genes of microRNA-21. Chin J Cancer. 2011;30:371–80.
38. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400–14.
39. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16:17–44.
40. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, et al. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer. 2015;15:184.